<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS97919</article-id>
<article-id pub-id-type="doi">10.1101/2020.10.09.332734</article-id>
<article-id pub-id-type="archive">PPR224494</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhao</surname>
<given-names>Dan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Xu</surname>
<given-names>Weifan</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhang</surname>
<given-names>Xiaofan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xiaoting</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Enming</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xiong</surname>
<given-names>Yuanpeng</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Shenyang</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Shuya</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Nian</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Tingzhong</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feng</surname>
<given-names>Xiaolong</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shu</surname>
<given-names>Hantao</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lang</surname>
<given-names>Peng</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Xiaokun</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Haitao</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Pilong</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zeng</surname>
<given-names>Jianyang</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China</aff>
<aff id="A2">
<label>2</label>Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Tsinghua University-Peking University Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China</aff>
<aff id="A3">
<label>3</label>Silexon AI Technology Co., Ltd., Nanjing, Jiangsu Province, China</aff>
<aff id="A4">
<label>4</label>Bioinformatics Division, BNRIST/Department of Computer Science and Technology, Tsinghua University, Beijing, China</aff>
<aff id="A5">
<label>5</label>Protein Preparation and Identification Facility, Technology Center for Protein Science, Tsinghua University, Beijing, China</aff>
<aff id="A6">
<label>6</label>Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China</aff>
<aff id="A7">
<label>7</label>Convalife (Shanghai) Co., Ltd., Shanghai, China</aff>
<aff id="A8">
<label>8</label>Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China</aff>
<aff id="A9">
<label>9</label>MOE Key Laboratory of Bioinformatics, Tsinghua University, Beijing, China</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>
<email>pilongli@mail.tsinghua.edu.cn</email>; <email>zengjy321@tsinghua.edu.cn</email>.</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>12</day>
<month>10</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The ongoing coronavirus disease 2019 (COVID-19) pandemic has raised an urgent need to develop effective therapeutics against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As a potential antiviral drug target, the nucleocapsid (N) protein of SARS-CoV-2 functions as a viral RNA chaperone and plays vital and multifunctional roles during the life cycle of coronavirus<sup>
<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref>
</sup>. In this study, we discovered that the N protein of SARS-CoV-2 undergoes liquid-liquid phase separation (LLPS) both <italic>in vitro</italic> and <italic>in vivo</italic>, which is further modulated by viral RNA. In addition, we found that, the core component of the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, nsp12, preferentially partitions into the N protein condensates. Moreover, we revealed that, two small molecules, i.e., CVL218 and PJ34, can be used to intervene the N protein driven phase separation and loosen the compact structures of the condensates of the N-RNA-nsp12 complex of SARS-CoV-2. The discovery of the LLPS-mediated interplay between N protein and nsp12 and the corresponding modulating compounds illuminates a feasible way to improve the accessibility of antiviral drugs (e.g., remdesivir) to their targets (e.g., nsp12/RdRp), and thus may provide useful hints for further development of effective therapeutic strategies against SARS-CoV-2.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="P2">To date, tens of millions of people have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the outbreak of the respiratory disease named the coronavirus disease 2019 (COVID-19). As a newly emerged member of the coronavirus family, SARS-CoV-2 is an enveloped positive-strand RNA virus, which has probably the largest genome (approximately 30 kb) among all RNA viruses. The nucleocapsid (N) protein of SARS-CoV-2 is mainly responsible for recognizing and wrapping viral RNA into helically symmetric structures, and thus insulates the viral genome from external environment<sup>
<xref ref-type="bibr" rid="R1">1</xref>
</sup>. It was also reported that N protein can boost the efficiency of transcription and replication of viral RNA, implying its vital and multifunctional roles in the life cycle of coronavirus<sup>
<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref>
</sup>. Considering the abundant expression and high immunogenicity of N protein during viral infection, accumulating studies have been performed to investigate the potential of N protein to serve as an antiviral drug target<sup>
<xref ref-type="bibr" rid="R4">4</xref>–<xref ref-type="bibr" rid="R7">7</xref>
</sup>.</p>
<p id="P3">In recent years, liquid-liquid phase separation (LLPS) has been shown to offer a highly efficient mechanism to spatially and temporally modulate the cellular processes, such as signaling transduction<sup>
<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>
</sup>, transcriptional control<sup>
<xref ref-type="bibr" rid="R10">10</xref>–<xref ref-type="bibr" rid="R12">12</xref>
</sup> and chromosome remodeling<sup>
<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref>
</sup>. Currently, more and more researches have shown that LLPS also participates in multiple aspects of viral infection, including viral replication, transcriptional regulation, and the formation of stress granules to modulate host immune response<sup>
<xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R22">22</xref>
</sup>. In general, viral transcription and replication tend to take place in a specific intracellular compartment called viral factory or viral inclusion<sup>
<xref ref-type="bibr" rid="R22">22</xref>–<xref ref-type="bibr" rid="R24">24</xref>
</sup>, and particularly the replication and transcription complexes (RTCs) in coronaviruses<sup>
<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref>
</sup>. Recent studies on negative-strand RNA viruses such as rabies virus, vesicular stomatitis virus (VSV) and measles virus (MeV), have indicated that LLPS is a common mechanism for N protein and phosphoprotein (P protein) to form viral inclusion-like structures<sup>
<xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R19">19</xref>
</sup>. Despite these known evidences of LLPS in negative-strand RNA viruses, it is unclear whether the N protein of SARS-CoV-2 or other coronaviruses undergoes LLPS and how the N protein driven phase separation participates in viral multiplication.</p>
<p id="P4">In this study, we determined the unique characteristics of the phase separation driven by the N protein of SARS-CoV-2 (termed SARS-CoV-2-N) both <italic>in vitro</italic> and <italic>in vivo</italic>. The influence of individual protein domains, mutations and nucleic acids on the phase condensation of SARS-CoV-2-N was also depicted. Importantly, the interplay between the N protein-viral RNA complex of SARS-CoV-2 (termed SARS-CoV-2-N-RNA) and nsp12, the key component of the coronavirus RTCs, was demonstrated to be mediated by LLPS. Furthermore, we found that two small molecules targeting the SARS-CoV-2-N are able to intervene the phase separation properties of the N protein-viral RNA-nsp12 (termed SARS-CoV-2-N-RNA-nsp12) complex, which may improve the accessibility of other antiviral drugs (e.g., remdesivir) to their viral targets (e.g., nsp12/RdRp). Our findings thus open a new opportunity for developing efficacious therapeutics against SARS-CoV-2.</p>
<sec id="S1" sec-type="results">
<title>Results</title>
<sec id="S2">
<title>SARS-CoV-2-N undergoes phase separation <italic>in vitro</italic> and <italic>in vivo</italic>
</title>
<p id="P5">The nucleocapsid (N) protein of SARS-CoV-2 (termed SARS-CoV-2-N), in common with that of other coronaviruses, contains an N-terminal RNA-binding domain (NTD) and a dimerization domain at its C terminus (CTD) (<xref ref-type="fig" rid="F1">Fig. 1a</xref> and see <xref ref-type="fig" rid="F6">Extended Data Fig. 1</xref>). The remaining domains of SARS-CoV-2-N are highly disordered, and contain three intrinsically disordered regions (IDRs), with one also displaying prion-like activity, according to the predictions using IUPred2<sup>
<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref>
</sup> and PLAAC<sup>
<xref ref-type="bibr" rid="R30">30</xref>
</sup> programs (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). As accumulating evidence has shown that the proteins with intrinsically disordered and prion-like properties are generally prone to undergo liquid-liquid phase separation (LLPS)<sup>
<xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R34">34</xref>
</sup>, it is natural to ask whether SARS-CoV-2-N also displays the LLPS characteristics. To answer this question, we first expressed and purified the recombinant SARS-CoV-2-N protein with an mEGFP-tag (a monomeric variant of EGFP, A206K) or a His-tag using a prokaryotic expression system (see <xref ref-type="fig" rid="F7">Extended Data Fig. 2a, b</xref>). Confocal fluorescence microscopy showed that SARS-CoV-2-N readily self-associated to form numerous micron-sized spherical condensates (<xref ref-type="fig" rid="F1">Fig. 1b, c</xref>). Further time-lapse observations revealed that the SARS-CoV-2-N condensates fused and coalesced into larger ones upon their intersections (<xref ref-type="fig" rid="F1">Fig. 1d</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Video 1</xref>), indicating the liquid-like properties of SARS-CoV-2-N condensates. We also used fluorescence recovery after photobleaching (FRAP) to further study the dynamics of internal molecules within the N protein condensates. Recovery of fluorescence within the bleached regions (<xref ref-type="fig" rid="F1">Fig. 1e</xref>) showed that SARS-CoV-2-N can partially freely diffuse within the condensed phase, consistent with their liquid-like behavior. In addition, phase condensation of SARS-CoV-2-N was sensitive to increasing ionic strength (<xref ref-type="fig" rid="F1">Fig. 1f</xref>): at low protein or high salt concentrations, SARS-CoV-2-N remained dissolved in solution and no droplets were observed, whereas at high protein or low salt concentrations, it condensed into droplets, suggesting that electrostatic interactions are important for its condensation. Collectively, the above results demonstrated that SARS-CoV-2-N is capable of undergoing LLPS <italic>in vitro</italic>.</p>
<p id="P6">Next, we examined whether SARS-CoV-2-N can also undergo LLPS <italic>in vivo</italic>, by ectopically expressing an mCherry tagged version of SARS-CoV-2-N in cells. We observed that SARS-CoV-2-N formed numerous puncta-like structures upon expression in Vero E6 cells (<xref ref-type="fig" rid="F1">Fig. 1g</xref>). We further evaluated the dynamicity of SARS-CoV-2-N within these puncta using FRAP, and the spatiotemporal analysis of bleaching events showed that SARS-CoV-2-N redistributed rapidly from the unbleached area to the bleached one (<xref ref-type="fig" rid="F1">Fig. 1g, h</xref>). In addition, time-lapse observations revealed that the SARS-CoV-2-N puncta fused into larger condensates right after their interactions (<xref ref-type="fig" rid="F1">Fig. 1i</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Video 2</xref>). All together, these results showed that SARS-CoV-2-N is also able to undergo LLPS <italic>in vivo</italic>.</p>
</sec>
<sec id="S3">
<title>Viral RNA modulates phase condensation of SARS-CoV-2-N</title>
<p id="P7">It was previously reported that the N protein of coronavirus prefers to bind to the intergenic regions and exhibits high binding affinity with the UCUAA pentanucleotide repeats<sup>
<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref>
</sup>. Given this fact, it would be interesting to know whether viral RNA can affect the phase separation behavior of SARS-CoV-2-N. To investigate this problem, we synthesized a 30-nt single-strand RNA of SARS-CoV-2 (genomic region 28,248-28,277), which contained a UCUAA pentanucleotide and was labeled with Cy5. We found that the addition of this viral RNA to the purified SARS-CoV-2-N solution at a physiological salt concentration (150 mM NaCl) resulted in robust co-phase separation of these two components, which was more predominant than that of a single one alone (<xref ref-type="fig" rid="F2">Fig. 2a</xref>). Compared to the condensates of SARS-CoV-2-N alone (<xref ref-type="fig" rid="F1">Fig. 1d</xref>), the droplets of N protein-RNA (termed SARS-CoV-2-N-RNA) complex were more spherical (<xref ref-type="fig" rid="F2">Fig. 2b</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Video 3</xref>). In addition, the condensates of SARS-CoV-2-N-RNA complex exhibited slightly higher molecular exchange rates than those of N protein alone (<xref ref-type="fig" rid="F1">Fig. 1e</xref>, <xref ref-type="fig" rid="F2">2c</xref>). To further study the phase separation properties of this two-component (i.e., N protein and nucleic acid) system under different conditions, we examined its condensation behaviors at different constituents. As in other two-component phase separation systems<sup>
<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R37">37</xref>
</sup>, the complex of SARS-CoV-2-N and viral RNA also exhibited an optimal molecular ratio of condensation (<xref ref-type="fig" rid="F2">Fig. 2d, e</xref>). Moreover, although the synthesized viral RNA, the host-derived RNA (β-actin RNA), the dsRNA and the ssDNA (both derived from viral RNA sequence) all induced phase separation, viral RNA displayed the most prominent effect (<xref ref-type="fig" rid="F2">Fig. 2f g</xref>) in regulating the LLPS of SARS-CoV-2-N. Thus, viral RNA plays a dominant role in promoting the phase separation of SARS-CoV-2-N <italic>in vitro</italic>, and modulating the liquid-like properties of the resulting condensates.</p>
</sec>
<sec id="S4">
<title>The intact structure of SARS-CoV-2-N is crucial to phase separation</title>
<p id="P8">To determine the contributions of individual domains of SARS-CoV-2-N to its phase separation, we first designed and expressed five truncations using a prokaryotic expression system (<xref ref-type="fig" rid="F3">Fig. 3a</xref> and see <xref ref-type="fig" rid="F7">Extended Data Fig. 2a</xref>) and then examined their phase separation properties at various ratios of N protein to viral RNA (<xref ref-type="fig" rid="F3">Fig. 3b</xref>). For a protein/RNA ratio of 1 or 2 (i.e., 1.5 μM protein/1.5 μM RNA or 3 μM protein/1.5 μM RNA, respectively), only full-length (FL) SARS-CoV-2-N exhibited the ability to phase separate (<xref ref-type="fig" rid="F3">Fig. 3b</xref>). When the protein/RNA ratio reached 4 or even 8 (i.e., 6 μM protein/1.5 μM RNA or 12 μM protein/1.5 μM RNA, respectively), although the truncations also formed phase-separated condensates, their LLPS ability was much weaker than that of the full-length SARS-CoV-2-N protein (<xref ref-type="fig" rid="F3">Fig. 3b, c</xref>). All these results indicated that all domains contribute to phase separation of SARS-CoV-2-N.</p>
</sec>
<sec id="S5">
<title>Spontaneous mutations impair phase separation of SARS-CoV-2-N</title>
<p id="P9">Since the first genome was sequenced in January 2020, 61,003 genome sequences of SARS-CoV-2 have been deposited into the China National Center for Bioinformation, 2019 Novel Coronavirus Resource<sup>
<xref ref-type="bibr" rid="R39">39</xref>
</sup> (<ext-link ext-link-type="uri" xlink:href="https://bigd.big.ac.cn/ncov?lang=en">https://bigd.big.ac.cn/ncov?lang=en</ext-link>, July 6th, 2020). Based on these available viral genomic data, although a large number of mutations have been discovered<sup>
<xref ref-type="bibr" rid="R40">40</xref>,<xref ref-type="bibr" rid="R41">41</xref>
</sup>, their influence on virulence and pathogenicity of SARS-CoV-2 still remains largely unknown. To study the effects of mutations on the LLPS of SARS-CoV-2-N, we first collected all the missense mutations within the N protein region (between genome positions 28,274 and 29,530) (<xref ref-type="fig" rid="F3">Fig. 3d</xref>). Notably, the serine-arginine (SR) rich region in the IDR2 domain of SARS-CoV-2-N was the hot spot, and harbored 7 of the top 10 most frequent mutations. The SR residues are generally considered potential phosphorylation sites, and the alternation of their phosphorylation states can impact both RNA binding and intracellular transportation of the N protein of coronavirus<sup>
<xref ref-type="bibr" rid="R42">42</xref>–<xref ref-type="bibr" rid="R45">45</xref>
</sup>. Among all the known missense mutations in SARS-CoV-2-N, R203K was of the highest frequency and always associated with other mutations (<xref ref-type="fig" rid="F3">Fig. 3d</xref>), indicating that probably it was one of the earliest mutations. Next, we expressed and purified a number of mutated SARS-CoV-2-N protein <italic>in vitro,</italic> including R203K, S194L, S197L, and S188L mutants (4 among the top 5 mutations) (see <xref ref-type="fig" rid="F7">Extended Data Fig. 2b</xref>), and then examined their phase separation capacity. Interestingly, these mutants displayed markedly weaker phase separation than the wild-type N protein (<xref ref-type="fig" rid="F3">Fig. 3e</xref>). Thus, it is conceivable that the SR rich region acts as a regulatory hub to modulate the biological functions of SARS-CoV-2-N through turning its phase separation properties.</p>
</sec>
<sec id="S6">
<title>CVL218 and PJ34 interact with SARS-CoV-2-N and affect the internal dynamics of its condensates</title>
<p id="P10">Considering the phase separation properties of SARS-CoV-2-N <italic>in vitro</italic> and <italic>in vivo</italic>, we want to know whether there exist small molecules or drugs that can intervene the viral life cycle through changing the condensation of this protein. According to our previous study, two poly ADP-ribose polymerase (PARP) inhibitors, CVL218 and PJ34, exhibit binding potential to SARS-CoV-2-N, as discovered by a machine learning based drug repositioning strategy<sup>
<xref ref-type="bibr" rid="R6">6</xref>
</sup>. Our surface plasmon resonance (SPR) assays confirmed that these two small molecules both interact with SARS-CoV-2-N, with CVL218 showing a higher binding affinity (<italic>K</italic>
<sc>D</sc>=4.7 μM, <xref ref-type="fig" rid="F4">Fig.4a</xref>) than PJ34 (<italic>K</italic>
<sc>D</sc>=696 μM, <xref ref-type="fig" rid="F4">Fig. 4b</xref>). Since the N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2-N are highly conserved and play important roles in RNA binding and self-dimerization<sup>
<xref ref-type="bibr" rid="R46">46</xref>
</sup>, we next investigated whether they are responsible for the interactions with these two small molecules. Unexpectedly, neither NTD nor CTD alone bound to CVL218 or PJ34 according to our <italic>in vitro</italic> SPR results (see <xref ref-type="fig" rid="F8">Extended Data Fig. 3</xref>), implying that the entire structure and conformation of SARS-CoV-2-N, including NTD, CTD and IDRs, are essential for the interactions with CVL218 or PJ34.</p>
<p id="P11">Next, we examined whether CVL218 and PJ34 can influence the phase separation behavior of SARS-CoV-2-N with viral RNA. We observed that the addition of CVL218 or PJ34 had little effect on the number or morphology of the puncta of SARS-CoV-2-N-RNA complex, comparing to DMSO treatment (<xref ref-type="fig" rid="F4">Fig. 4c</xref>). Nevertheless, the fluorescence intensity of the condensates with CVL218 or PJ34 treatment recovered faster than that with DMSO treatment after photobleaching (<xref ref-type="fig" rid="F4">Fig. 4d, e</xref>), demonstrating that CVL218 and PJ34 can both enhance the internal mobility of the condensates of SARS-CoV-2-N-RNA complex.</p>
</sec>
<sec id="S7">
<title>Nsp12 can be recruited into the SARS-CoV-2-N-RNA condensates</title>
<p id="P12">Nsp12, a core component of RNA dependent RNA polymerase (RdRp) complex in SARS-CoV-2, forms the coronavirus transcription and replication machinery with nsp7 and nsp8 together (<xref ref-type="fig" rid="F5">Fig. 5a</xref>). It was previously reported that N protein can cooperate with RdRp to facilitate viral infection<sup>
<xref ref-type="bibr" rid="R25">25</xref>
</sup>. However, the underlying mechanisms still remain largely obscure. To further explore whether the interplay between N protein and RdRp of SARS-CoV-2 is mediated by phase separation, we also purified the nsp12 protein (see <xref ref-type="fig" rid="F7">Extended Data Fig. 2c</xref>) and examined its potential involvement in LLPS. We observed that nsp12 alone cannot undergo phase separation under physiological salt condition (<xref ref-type="fig" rid="F5">Fig. 5b</xref>), whereas it readily converted to amorphous condensates when mixed with viral RNA (see <xref ref-type="fig" rid="F9">Extended Data Fig. 4</xref>). In addition, FRAP assays indicated that the fluorescence intensity of nsp12-RNA condensates cannot recover after photobleaching (<xref ref-type="supplementary-material" rid="SD1">Supplementary Video 4</xref>), implying that little molecular exchange occurs within the resulting solid-state condensates. Nevertheless, we found that nsp12 can be readily recruited into the SARS-CoV-2-N-RNA condensates without changing their morphological shapes and arrangements (<xref ref-type="fig" rid="F5">Fig. 5b</xref>). Here, the highly concentrated condensates of SARS-CoV-2-N-nsp12 complex may provide a favorable condition for fast viral replication <italic>in vivo</italic>.</p>
</sec>
<sec id="S8">
<title>CVL218 and PJ34 affect the morphology and condensation properties of SARS-CoV-2-N-RNA-nsp12 complex.</title>
<p id="P13">Next, we sought to examined whether CVL218 or PJ34 can affect the phase condensation properties of SARS-CoV-2-N-RNA-nsp12 complex. Interestingly, the sizes of SARS-CoV-2-N-RNA-nsp12 condensates in the CVL218 or PJ34 treated group were much larger than those of the corresponding group without nsp12 (<xref ref-type="fig" rid="F5">Fig. 5d-e</xref> and see <xref ref-type="fig" rid="F10">Extended Data Fig. 5</xref>). More importantly, no matter with or without nsp12, the sizes of SARS-CoV-2-N-RNA condensates under CVL218 or PJ34 treatment were significantly larger than those of the DMSO treated group (<xref ref-type="fig" rid="F5">Fig. 5c-f</xref>). Moreover, FRAP assays indicated that the fluorescence recovery rates of SARS-CoV-2-N-RNA-nsp12 condensates were faster in the CVL218 or PJ34 treated group than those of the control treatment (<xref ref-type="fig" rid="F5">Fig. 5g, h</xref>). Thus, our results suggested that CVL218 and PJ34 can induce a more dynamic condition to facilitate the intermolecular exchange of internal molecules within the droplets of SARS-CoV-2-N-RNA-nsp12 complex <italic>in vitro</italic>. The accelerating exchange rates of internal molecules within the droplets may loosen the solid-state condensation of the nsp12-containing RdRp complex and thus benefit the entrance of other antiviral drugs (e.g., remdesivir) into their targets (e.g., nsp12/RdRp).</p>
</sec>
</sec>
<sec id="S9" sec-type="discussion">
<title>Discussion</title>
<p id="P14">Our results showed that the N protein of SARS-CoV-2 is capable of undergoing LLPS, and extra addition of viral RNA further facilitates its phase separation, which has also been recently confirmed by several independent research teams<sup>
<xref ref-type="bibr" rid="R47">47</xref>–<xref ref-type="bibr" rid="R49">49</xref>
</sup>. Moreover, with in-depth study, we discovered that nsp12/RdRp can be recruited into the condensates of SARS-CoV-2-N-RNA complex. Furthermore, in terms of the intervention of the SARS-CoV-2-N driven phase separation, we set up an experimental workflow for compound verification and proposed a conceptual framework for developing the small molecule-based therapeutics against SARS-CoV-2, based on a rationale of combination therapy to target both N protein and nsp12/RdRp.</p>
<p id="P15">Our work suggests that LLPS is likely to be the driving force of the connection between N protein and the replication and transcription complexes (RTCs), and thus altering the N-driven LLPS can possibly intervene viral multiplication and infection. Normally, many non-structural proteins (nsps) of coronavirus anchor in double-membrane vesicles and convoluted membranes and are packaged into RTCs in infected cells<sup>
<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref>
</sup>. The dynamics of RTCs is generally relatively low, implying that they display relatively static structures and probably their communications with the surroundings rely on other components<sup>
<xref ref-type="bibr" rid="R26">26</xref>
</sup>. Yet, N protein is so far the only known structural protein of coronavirus that shuttles into and outside RTCs and plays a vital role in coordination with the RdRp complex<sup>
<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref>
</sup>. Likewise, in the negative-strand RNA viruses, a granular structure termed inclusion body particularly stays in cytoplasm serving as a site of viral replication and transcription<sup>
<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R22">22</xref>
</sup>. Interestingly, two structural proteins, i.e., N and P proteins, have been shown to be sufficient to spontaneously form an inclusion body-like structure mediated by LLPS in rabies virus, vesicular stomatitis virus (VSV) and measles virus (MeV)<sup>
<xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R19">19</xref>
</sup>. Here, we showed that in SARS-CoV-2, nsp12 can be recruited into the condensates of N protein, which are then turned to exhibit more liquid-like characteristics. Therefore, LLPS is probably an efficient mechanism to organize N protein and nsp12 together in SARS-CoV-2 to achieve fast viral replication. Of course, more evidence is needed to answer whether LLPS is a common mechanism for the formation of viral-specific compartments in other viruses.</p>
<p id="P16">Although extensive studies have been conducted on developing effective therapeutics against coronavirus through primarily targeting the spike protein and viral enzymes (e.g., nsp12/RdRp, 3C-like protease and papain-like protease), there is little success of these strategies. According to our results, we speculate that the LLPS characteristics of N protein may be one of the underlying reasons for the failure of many anti-coronavirus drugs. A related evidence comes from a recent study showing that a number of antineoplastic drugs cannot freely diffuse, but rather become partitioned in specific protein condensates <italic>in vitro</italic>
<sup>
<xref ref-type="bibr" rid="R50">50</xref>
</sup>. This result supports the hypothesis that altering the biophysical properties of condensates may improve the distribution and efficacy of drugs. In our study, we observed that <italic>in vitro</italic> nsp12 and viral RNA form amorphous condensates, implying that their complex is relatively immobile, which is also consistent with the previous observations on the dynamics of RTCs<sup>
<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref>
</sup>. The solid state of nsp12-RNA complex may exclude the nsp12 targeting drugs (e.g., remdesivir<sup>
<xref ref-type="bibr" rid="R51">51</xref>–<xref ref-type="bibr" rid="R53">53</xref>
</sup>) from the surrounding solution, which thus provides a possible explanation on why many nucleotide analog drugs as broad-spectrum viral RdRp inhibitors have poor performance in the treatment of coronavirus<sup>
<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R55">55</xref>
</sup>.</p>
<p id="P17">As a proof of concept on discovering an intervention of the N protein driven LLPS, we identified two small molecules, i.e., CVL218 and PJ34, with the ability to affect the condensation properties of the SARS-CoV-2-N-nsp12 complex. These two compounds can influence the morphology of the N protein driven condensates, and also augment their sizes <italic>in vitro</italic> (<xref ref-type="fig" rid="F5">Fig. 5f</xref>). Meanwhile, we also observed an increasing number of puncta of overexpressed mCherry-N in Vero-E6 cells, after CVL218/PJ34 treatment (see <xref ref-type="fig" rid="F11">Extended Data Fig. 6a, b</xref>). In addition, these two small molecules both tune the SARS-CoV-2-N-nsp12 droplets to become more liquid-like, thus increasing the exchange with the surrounding solution and attenuating the molecular interactions within the condensates. Based on these observations, we speculate that CVL218 and PJ34 may act as bulking agents to reduce the local density of the SARS-CoV-2-N-nsp12 condensates. The increasing penetrability may possibly contribute to the access of other small-molecule drugs into the condensates. Therefore, we propose that CVL218 or PJ34 can be applied to facilitate the entrance of other antiviral drugs (e.g., remdesivir<sup>
<xref ref-type="bibr" rid="R51">51</xref>–<xref ref-type="bibr" rid="R53">53</xref>
</sup>) into RTCs by remodeling the communications between N protein and RTCs and promoting the permeability of RTCs (<xref ref-type="fig" rid="F5">Fig. 5i</xref>). Our results suggest that the N protein driven LLPS is a promising target for the design of antiviral drugs, and the deep understanding into the functional roles of N protein in regulating the accessibility of RTCs will thus advance the development of anti-SARS-CoV-2 therapies.</p>
</sec>
<sec id="S10" sec-type="methods">
<title>Methods</title>
<sec id="S11">
<title>Cell culture and transfection</title>
<p id="P18">Vero E6 cells were kindly provided by Dr. Yiyue Ge and Dr. Jingxin Li from NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention. Vero E6 cells were cultured in Dulbecco's modified Eagle's medium (HyClone) supplemented with 10% fetal bovine serum (HyClone SH30071.03 and SH30396.03) and maintained at 37℃ in a humidified incubator with 5% CO<sub>2</sub>. FuGENE 6 (Promega, E2691) was used for transient transfection according to the manufacturer's instructions.</p>
</sec>
<sec id="S12">
<title>Construction of recombinant plasmids</title>
<p id="P19">The recombinant plasmids of pET28a-N and pET22b-nsp12 were kindly provided by Cellregen Co., Ltd. and Prof. Zhiyong Lou<sup>
<xref ref-type="bibr" rid="R56">56</xref>
</sup>, respectively. The mutants of pET28a-N were constructed by seamless cloning kits (Beyotime, D7010M) and confirmed by sequencing. For the construction of mEGFP-N plasmids, the full-length gene and truncations of SARS-CoV-2-N were both cloned into a PL118 vector (an in-house modified vector based on pRSFDuet1) containing an N-terminal 6×his-mEGFP tag, respectively. The full-length gene of SARS-CoV-2-N was cloned into a pCDNA3.1 vector containing an N-terminal mCherry tag. The detailed primer sequences are listed in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>.</p>
</sec>
<sec id="S13">
<title>Protein expression and purification</title>
<p id="P20">The recombinant full-length mEGFP-N protein and truncations were overexpressed in <italic>E. coli</italic> BL21 (DE3). After overnight induction by 0.2mM isopropyl β-D-thiogalactoside (IPTG) at 16 °C in LB medium, cells were harvested and suspended in the buffer (40mM HEPES, pH 7.5, 1M NaCl, 20mM imidazole and 2mM phenylmethylsulfonyl fluoride). After cell lysis and centrifugation, the recombined proteins were purified to homogeneity over HisTrap column and eluted with a linear imidazole gradient from 20 mM to 500 mM. The proteins were further purified by size-exclusion chromatography using a Superdex 200 Increase 10/300 GL column (GE Healthcare) in elution buffer (40 mM HEPES, pH7.5, 1M NaCl, 5% glycerol, 1 mM EGTA, 1 mM MgCl2). The purification procedures of the recombinant wild-type pET28a-N protein and mutants were essentially the same as that of the mEGFP-N protein except for a different size-exclusion chromatography buffer (20mM Tris, pH 7.5, 300mM NaCl).</p>
</sec>
<sec id="S14">
<title>Protein labeling</title>
<p id="P21">All pET28a-N proteins (WT and mutants) and nsp12 protein were labeled by incubating with a 1:1 molar ratio of Alexa Fluor™ 546 carbox (Thermo Fisher Scientific) for 1 h at room temperature with continuous stirring. Then, the free dyes were removed by centrifugation in MICROSPIN G-50 column (GE Healthcare, 27-5330-01). The labeled proteins were stored at −80°C. For <italic>in vitro</italic> phase separation experiments, 5% labeled protein was mixed with unlabeled before use.</p>
</sec>
<sec id="S15">
<title>Synthesis of RNA and DNA</title>
<p id="P22">The 5'-Cy5-labeled 10-bp viral RNA oligo (AGCUGAUGAG) and 30-bp RNA oligos (viral RNA: GAUUUCAUCUAAACGAACAAACUAAAAUGU; human β actin RNA: UCACCAACUGGGACGACAUGGAGAAAAUCU) with were synthesized at HIPPOBIO, LLC. The double-strand RNA was annealed at 25 μM in the annealing buffer (40 mM HEPES, pH 7.4, and 150 mM NaCl) using a thermocycler, during which the oligos were heated up to 95 °C for 2 min and gradually cooled to 25°C over an hour.</p>
</sec>
<sec id="S16">
<title>Phase separation assays</title>
<p id="P23">
<italic>In vitro</italic> LLPS experiments were performed at room temperature. All samples were seeded and recorded on 384 low-binding multi-well 0.17 mm microscopy plates (In Vitro Scientific) and sealed with optically clear adhesive film. For phase separation assays with the mEGFP-N protein of SARS-CoV-2, solutions of GFP fusion proteins were diluted to the indicated final concentrations in 20 mM HEPES, pH 7.4, 500 mM NaCl, 5% glycerol, 1 mM EGTA and 1mM MgCl<sub>2</sub> in a total volume of 10 μl to induce phase separation. For the N proteins without tags, the assays were performed in 20 mM Tris-HCl, pH 7.5 and 150 mM NaCl. For phase separation assays treated with small molecules, CVL218 or PJ34 (dissolved in 1% DMSO) were added to the well mixed phase separation samples prior to imaging at a final concentration of 20 μM. The group treated with 1% DMSO was used as the control.</p>
<p id="P24">For <italic>in vivo</italic> assays, Vero E6 cells were seeded into 4-well chamber 35 mm dishes with a density of 5 × 10<sup>5</sup> cells/well. For cells to reach 70% confluent, 1 μg pCDNA3.1-mcherry-N plasmid was transfected, with the replacement of normal cell culture medium by that supplemented with CVL218 or PJ34 at a final concentration of 20 μM. For the control wells, cell medium containing 1% DMSO was added. Imaging was performed with a NIKON A1 microscope equipped with a 100× oil immersion objective. NIS-Elements AR Analysis was used to analyze the images.</p>
</sec>
<sec id="S17">
<title>Fluorescence recovery after photobleaching (FRAP) measurements <italic>in vivo</italic> and <italic>in vitro</italic>
</title>
<p id="P25">FRAP experiments were carried out with a NIKON A1 microscope equipped with a 100× oil immersion objective. Droplets were bleached with the corresponding laser pulse (3 repeats, 80% intensity, and dwell time 1 s). Recovery from photobleaching was recorded for the indicated time point.</p>
</sec>
<sec id="S18">
<title>Mutation frequency analysis</title>
<p id="P26">To perform the mutation frequency analysis of SARS-CoV-2-N protein, we used 61,003 SARS-CoV-2 genome sequences downloaded from the China National Center for Bioinformation, 2019 Novel Coronavirus Resource<sup>
<xref ref-type="bibr" rid="R39">39</xref>
</sup> (downloaded on July 6th, 2020). We considered all the missense mutations among the N protein region (from positions 28,274 to 29,530 in the genome).</p>
</sec>
<sec id="S19">
<title>Surface plasmon resonance assays</title>
<p id="P27">Surface plasmon resonance (SPR) assays were performed on Biacore S200 with a CM5 sensor chip (GE Healthcare Life Sciences) at room temperature. The full-length N protein, NTD and CTD of SARS-CoV-2 were all diluted in 10 mM sodium acetate (pH 5.0) and immobilized on a CM5 sensor chip by amine coupling. The running buffer contained 1×PBS-P with 2% DMSO. The tested drugs (CVL218 or PJ34) in 2-fold serial dilutions were made in the running buffer. The solutions flowed through the chip surface at a flow rate of 20 μL/min at room temperature (25℃). The dissociation constants (<italic>K</italic>
<sub>D</sub>) of CVL218 and PJ34 binding to full-length N protein, NTD and CTD were calculated from the association and dissociation curves of the sensorgrams using the BIA evaluation program (Biacore).</p>
</sec>
</sec>
<sec id="S20" sec-type="extended-data">
<title>Extended Data</title>
<fig id="F6" position="anchor">
<label>Extended Data Fig.1</label>
<caption>
<title>Multiple sequence alignment of the N proteins from different human coronaviruses.</title>
<p id="P28">The nucleocapsid (N) protein sequences of the currently known coronaviruses that can infect human, including SARS-CoV-2 (GenBank: QHD43423.2), SARS-CoV (GenBank: AYV99827.1), MERS-CoV (GenBank: AVV62544.1), HCoV-OC43 (GenBank: AAR01019.1), HCoV-229E (GenBank: APD51511.1), HCoV-NL63 (NCBI Reference Sequence: YP_009328939.1) and HCoV-HKU1 (GenBank: ARU07581.1), were aligned using MUSCLE<sup>
<xref ref-type="bibr" rid="R38">38</xref>
</sup>. Domain architectures are depicted above the sequence alignment. The conserved residues are shaded in red, while those with the percentage of conservation larger than or equal to 50% are shaded in blue.</p>
</caption>
<graphic xlink:href="EMS97919-f006"/>
</fig>
<fig id="F7" position="anchor">
<label>Extended Data Fig.2</label>
<caption>
<title>SDS-PAGE of the purified recombinant proteins of SARS-CoV-2-N used in <italic>in vitro</italic> assays.</title>
<p id="P29">
<bold>a</bold>, The mEGFP-tagged full-length (FL) and truncated proteins of SARS-CoV-2-N. <bold>b</bold>, The wild-type and mutant proteins of SARS-CoV-2-N with His-tagged at the N terminus. <bold>c</bold>. The nsp12 protein of SARS-CoV-2. The gel was stained with Coomassie Brilliant Blue.</p>
</caption>
<graphic xlink:href="EMS97919-f007"/>
</fig>
<fig id="F8" position="anchor">
<label>Extended Data Fig.3</label>
<caption>
<title>CLV218 and PJ34 do not directly bind to the NTD and CTD of SARS-CoV-2-N.</title>
<p id="P30">
<bold>a, b,</bold> Surface plasmon resonance (SPR) assays of CVL218 (<bold>a</bold>) and PJ34 (<bold>b</bold>) to the immobilized N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2-N.</p>
</caption>
<graphic xlink:href="EMS97919-f008"/>
</fig>
<fig id="F9" position="anchor">
<label>Extended Data Fig.4</label>
<caption>
<title>Nsp12 and viral RNA of SARS-CoV-2 form amorphous condensates <italic>in vitro</italic>.</title>
<p id="P31">Fluorescence microscopy images of 3 μM Alx546-labeled nsp12 (purple) mixed with 3 μM Cy5-labeled viral RNA (red) of SARS-CoV-2. Scale bar, 5 μm.</p>
</caption>
<graphic xlink:href="EMS97919-f009"/>
</fig>
<fig id="F10" position="anchor">
<label>Extended Data Fig.5</label>
<caption>
<title>The recruitment of nsp12 enlarges the sizes of the SARS-CoV-2-N-RNA condensates.</title>
<p id="P32">Supplementary quantitative comparison of average diameters of the condensates in the presence and absence of nsp12 presented in <xref ref-type="fig" rid="F5">Fig.5 c, d, e</xref>. The diameters were measured from the fluorescence microscopy images and shown as mean±SD over three independent experiments. P values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparison test, ***: P &lt; 0.001, ****: P &lt; 0.0001.</p>
</caption>
<graphic xlink:href="EMS97919-f010"/>
</fig>
<fig id="F11" position="anchor">
<label>Extended Data Fig.6</label>
<caption>
<title>CVL218 and PJ34 treatments influence the condensation of SARS-CoV-2-N <italic>in vivo</italic>.</title>
<p id="P33">
<bold>a</bold>, Droplet formation of the expressed mCherry-N (SARS-CoV-2-N tagged with mCherry) in Vero-E6 cells for 48h. Scale bar, 10 μm. <bold>b</bold>, Quantitative comparison of the numbers of droplets presented in <bold>a</bold>. In total 11 transfected cells were considered in each group (i.e., DMSO, CVL218-treated or PJ34-treated). Data are shown as mean±SD and P values were determined by one-way analysis of variance (ANOVA) with Dunnett's multiple comparison test, **: P &lt; 0.01, ****: P &lt; 0.0001.</p>
</caption>
<graphic xlink:href="EMS97919-f011"/>
</fig>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplemental Files</label>
<media xlink:href="EMS97919-supplement-Supplemental_Files.zip" mimetype="application" mime-subtype="zip" id="N66866" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S21">
<title>Acknowledgements</title>
<p>We thank Dr. Tingting Li for helpful discussions on phase separation. We acknowledge the assistance of Protein Preparation and Identification Facility (Technology Center for Protein Science, Tsinghua University) for protein expression and purification, High Throughput Screening (HTS) Core Facility for SPR experimental guidance (Center of Pharmaceutical Technology, Tsinghua University) and SLSTU-Nikon Biological Imaging Center (Center of Pharmaceutical Technology, Tsinghua University) for imaging support. This work was supported in part by the National Natural Science Foundation of China (61872216 and 81630103 to JZ, 31900862 to DZ, 31871443 to PL), the National Key R&amp;D Program (2019YFA0508403 to PL), the Turing AI Institute of Nanjing and the Zhongguancun Haihua Institute for Frontier Information Technology.</p>
</ack>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P34">
<bold>Author Contributions</bold>
</p>
<p id="P35">DZ, WX, PL and JZ conceived the research project. PL and JZ supervised the study. DZ, WX and XZ designed and performed experiments, and analyzed the data. XT, SW and XF performed protein expression and purification <italic>in vitro</italic>. EY, YX and PL analyzed the SARS-CoV-2 genomic data. NW and HS analyzed the structural data of SARS-CoV-2-N. XS supplied PJ34 and CVL218 and provided discussions on the SPR results. HL participated in the project discussion and provided suggestions. DZ, WX, XZ, PL and JZ wrote the manuscript with support from all authors.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malik</surname>
<given-names>YA</given-names>
</name>
</person-group>
<article-title>Properties of Coronavirus and SARS-CoV-2</article-title>
<source>Malays J Pathol</source>
<year>2020</year>
<volume>42</volume>
<fpage>3</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>TH</given-names>
</name>
</person-group>
<article-title>The SARS coronavirus nucleocapsid protein--forms and functions</article-title>
<source>Antiviral Res</source>
<year>2014</year>
<volume>103</volume>
<fpage>39</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2013.12.009</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surjit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lal</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>The SARS-CoV nucleocapsid protein: a protein with multifarious activities</article-title>
<source>Infect Genet Evol</source>
<year>2008</year>
<volume>8</volume>
<fpage>397</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1016/j.meegid.2007.07.004</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein</article-title>
<source>Drug Discov Today</source>
<year>2016</year>
<volume>21</volume>
<fpage>562</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1016/j.drudis.2015.11.015</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>SY</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target</article-title>
<source>J Med Chem</source>
<year>2014</year>
<volume>57</volume>
<fpage>2247</fpage>
<lpage>2257</lpage>
<pub-id pub-id-type="doi">10.1021/jm500089r</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ge</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.03.11.986836</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarma</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)</article-title>
<source>J Biomol Struct Dyn</source>
<year>2020</year>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1080/07391102.2020.1753580</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>PL</given-names>
</name>
<etal/>
</person-group>
<article-title>Phase transitions in the assembly of multivalent signalling proteins</article-title>
<source>Nature</source>
<year>2012</year>
<volume>483</volume>
<fpage>336</fpage>
<lpage>U129</lpage>
<pub-id pub-id-type="doi">10.1038/nature10879</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Case</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ditlev</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Stoichiometry controls activity of phase-separated clusters of actin signaling proteins</article-title>
<source>Science</source>
<year>2019</year>
<volume>363</volume>
<fpage>1093</fpage>
<lpage>1097</lpage>
<pub-id pub-id-type="doi">10.1126/science.aau6313</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boija</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains</article-title>
<source>Cell</source>
<year>2018</year>
<volume>175</volume>
<fpage>1842</fpage>
<lpage>+</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2018.10.042</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hnisz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shrinivas</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>A Phase Separation Model for Transcriptional Control</article-title>
<source>Cell</source>
<year>2017</year>
<volume>169</volume>
<fpage>13</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.02.007</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabari</surname>
<given-names>BR</given-names>
</name>
<etal/>
</person-group>
<article-title>Coactivator condensation at super-enhancers links phase separation and gene control</article-title>
<source>Science</source>
<year>2018</year>
<volume>361</volume>
<pub-id pub-id-type="doi">10.1126/science.aar3958</pub-id>
<comment>ARTN eaar3958</comment>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibson</surname>
<given-names>BA</given-names>
</name>
<etal/>
</person-group>
<article-title>Organization of Chromatin by Intrinsic and Regulated Phase Separation</article-title>
<source>Cell</source>
<year>2019</year>
<volume>179</volume>
<fpage>470</fpage>
<lpage>+</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2019.08.037</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larson</surname>
<given-names>AG</given-names>
</name>
<etal/>
</person-group>
<article-title>Liquid droplet formation by HP1 alpha suggests a role for phase separation in heterochromatin</article-title>
<source>Nature</source>
<year>2017</year>
<volume>547</volume>
<fpage>236</fpage>
<lpage>+</lpage>
<pub-id pub-id-type="doi">10.1038/nature22822</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lahaye</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Functional Characterization of Negri Bodies (NBs) in Rabies Virus-Infected Cells: Evidence that NBs Are Sites of Viral Transcription and Replication</article-title>
<source>J Virol</source>
<year>2009</year>
<volume>83</volume>
<fpage>7948</fpage>
<lpage>7958</lpage>
<pub-id pub-id-type="doi">10.1128/Jvi.00554-09</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinh</surname>
<given-names>PX</given-names>
</name>
<etal/>
</person-group>
<article-title>Induction of Stress Granule-Like Structures in Vesicular Stomatitis Virus-Infected Cells</article-title>
<source>J Virol</source>
<year>2013</year>
<volume>87</volume>
<fpage>372</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="doi">10.1128/Jvi.02305-12</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nikolic</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Negri bodies are viral factories with properties of liquid organelles</article-title>
<source>Nat Commun</source>
<year>2017</year>
<volume>8</volume>
<pub-id pub-id-type="doi">10.1038/s41467-017-00102-9</pub-id>
<comment>ARTN 58</comment>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Samuel</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Measles Virus Forms Inclusion Bodies with Properties of Liquid Organelles</article-title>
<source>J Virol</source>
<year>2019</year>
<volume>93</volume>
<pub-id pub-id-type="doi">10.1128/JVI.00948-19</pub-id>
<comment>ARTN e00948-19</comment>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heinrich</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Maliga</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Whelan</surname>
<given-names>SPJ</given-names>
</name>
</person-group>
<article-title>Phase Transitions Drive the Formation of Vesicular Stomatitis Virus Replication Compartments</article-title>
<source>Mbio</source>
<year>2018</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.1128/mBio.02290-17</pub-id>
<comment>ARTN e02290-17</comment>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>Q</given-names>
</name>
<etal/>
</person-group>
<article-title>Phase Separation of Epstein-Barr Virus EBNA2 and Its Coactivator EBNALP Controls Gene Expression</article-title>
<source>J Virol</source>
<year>2020</year>
<volume>94</volume>
<pub-id pub-id-type="doi">10.1128/JVI.01771-19</pub-id>
<comment>ARTN e01771-19</comment>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tawara</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Imagawa</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Fine Structure of Cellular Inclusions in Experimental Measles</article-title>
<source>Virology</source>
<year>1961</year>
<volume>14</volume>
<fpage>410</fpage>
<lpage>+</lpage>
<pub-id pub-id-type="doi">10.1016/0042-6822(61)90332-4</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoenen</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Inclusion Bodies Are a Site of Ebolavirus Replication</article-title>
<source>J Virol</source>
<year>2012</year>
<volume>86</volume>
<fpage>11779</fpage>
<lpage>11788</lpage>
<pub-id pub-id-type="doi">10.1128/Jvi.01525-12</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Netherton</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Wileman</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Virus factories, double membrane vesicles and viroplasm generated in animal cells</article-title>
<source>Curr Opin Virol</source>
<year>2011</year>
<volume>1</volume>
<fpage>381</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="doi">10.1016/j.coviro.2011.09.008</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novoa</surname>
<given-names>RR</given-names>
</name>
<etal/>
</person-group>
<article-title>Virus factories: associations of cell organelles for viral replication and morphogenesis</article-title>
<source>Biol Cell</source>
<year>2005</year>
<volume>97</volume>
<fpage>147</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1042/Bc20040058</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cong</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle</article-title>
<source>J Virol</source>
<year>2020</year>
<volume>94</volume>
<pub-id pub-id-type="doi">10.1128/JVI.01925-19</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagemeijer</surname>
<given-names>MC</given-names>
</name>
<etal/>
</person-group>
<article-title>Dynamics of coronavirus replication-transcription complexes</article-title>
<source>J Virol</source>
<year>2010</year>
<volume>84</volume>
<fpage>2134</fpage>
<lpage>2149</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01716-09</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verheije</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group>
<article-title>The coronavirus nucleocapsid protein is dynamically associated with the replication-transcription complexes</article-title>
<source>J Virol</source>
<year>2010</year>
<volume>84</volume>
<fpage>11575</fpage>
<lpage>11579</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00569-10</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erdos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dosztanyi</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Analyzing Protein Disorder with IUPred2A</article-title>
<source>Curr Protoc Bioinformatics</source>
<year>2020</year>
<volume>70</volume>
<fpage>e99</fpage>
<pub-id pub-id-type="doi">10.1002/cpbi.99</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meszaros</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Erdos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dosztanyi</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>IUPred2A: context-dependent prediction of protein disorder as a function of redox state and protein binding</article-title>
<source>Nucleic Acids Res</source>
<year>2018</year>
<volume>46</volume>
<fpage>W329</fpage>
<lpage>W337</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gky384</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lancaster</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Nutter-Upham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lindquist</surname>
<given-names>S</given-names>
</name>
<name>
<surname>King</surname>
<given-names>OD</given-names>
</name>
</person-group>
<article-title>PLAAC: a web and command-line application to identify proteins with prion-like amino acid composition</article-title>
<source>Bioinformatics</source>
<year>2014</year>
<volume>30</volume>
<fpage>2501</fpage>
<lpage>2502</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btu310</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elbaum-Garfinkle</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>The disordered P granule protein LAF-1 drives phase separation into droplets with tunable viscosity and dynamics</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2015</year>
<volume>112</volume>
<fpage>7189</fpage>
<lpage>7194</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1504822112</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nott</surname>
<given-names>TJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles</article-title>
<source>Mol Cell</source>
<year>2015</year>
<volume>57</volume>
<fpage>936</fpage>
<lpage>947</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2015.01.013</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>A Molecular Grammar Governing the Driving Forces for Phase Separation of Prion-like RNA Binding Proteins</article-title>
<source>Cell</source>
<year>2018</year>
<volume>174</volume>
<fpage>688</fpage>
<lpage>699 e616</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2018.06.006</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alberti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Halfmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>King</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kapila</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lindquist</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A systematic survey identifies prions and illuminates sequence features of prionogenic proteins</article-title>
<source>Cell</source>
<year>2009</year>
<volume>137</volume>
<fpage>146</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.02.044</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stohlman</surname>
<given-names>SA</given-names>
</name>
<etal/>
</person-group>
<article-title>Specific Interaction between Coronavirus Leader Rna and Nucleocapsid Protein</article-title>
<source>J Virol</source>
<year>1988</year>
<volume>62</volume>
<fpage>4288</fpage>
<lpage>4295</lpage>
<pub-id pub-id-type="doi">10.1128/Jvi.62.11.4288-4295.1988</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Stohlman</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Tahara</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>High affinity interaction between nucleocapsid protein and leader/intergenic sequence of mouse hepatitis virus RNA</article-title>
<source>J Gen Virol</source>
<year>2000</year>
<volume>81</volume>
<fpage>181</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1099/0022-1317-81-1-181</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guillen-Boixet</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>RNA-Induced Conformational Switching and Clustering of G3BP Drive Stress Granule Assembly by Condensation</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>346</fpage>
<lpage>361 e317</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2020.03.049</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edgar</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>MUSCLE: multiple sequence alignment with high accuracy and high throughput</article-title>
<source>Nucleic Acids Res</source>
<year>2004</year>
<volume>32</volume>
<fpage>1792</fpage>
<lpage>1797</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkh340</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>WM</given-names>
</name>
<etal/>
</person-group>
<article-title>The 2019 novel coronavirus resource</article-title>
<source>Yi Chuan</source>
<year>2020</year>
<volume>42</volume>
<fpage>212</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.16288/j.yczz.20-030</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Parida</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Variant analysis of SARS-CoV-2 genomes</article-title>
<source>Bull World Health Organ</source>
<year>2020</year>
<volume>98</volume>
<fpage>495</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="doi">10.2471/BLT.20.253591</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>The establishment of reference sequence for SARS-CoV-2 and variation analysis</article-title>
<source>J Med Virol</source>
<year>2020</year>
<volume>92</volume>
<fpage>667</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="doi">10.1002/jmv.25762</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables coronavirus transition from discontinuous to continuous transcription</article-title>
<source>Cell Host Microbe</source>
<year>2014</year>
<volume>16</volume>
<fpage>462</fpage>
<lpage>472</lpage>
<pub-id pub-id-type="doi">10.1016/j.chom.2014.09.009</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>CH</given-names>
</name>
<etal/>
</person-group>
<article-title>Glycogen synthase kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus nucleocapsid protein and viral replication</article-title>
<source>J Biol Chem</source>
<year>2009</year>
<volume>284</volume>
<fpage>5229</fpage>
<lpage>5239</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M805747200</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlson</surname>
<given-names>CR</given-names>
</name>
<etal/>
</person-group>
<article-title>Phosphorylation modulates liquid-liquid phase separation of the SARS-CoV-2 N protein</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.06.28.176248</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Tarn</surname>
<given-names>WY</given-names>
</name>
</person-group>
<article-title>Phosphorylation of the arginine/serine dipeptide-rich motif of the severe acute respiratory syndrome coronavirus nucleocapsid protein modulates its multimerization, translation inhibitory activity and cellular localization</article-title>
<source>FEBS J</source>
<year>2008</year>
<volume>275</volume>
<fpage>4152</fpage>
<lpage>4163</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2008.06564.x</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AMV</given-names>
</name>
<name>
<surname>Silletti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>KD</given-names>
</name>
</person-group>
<article-title>Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein</article-title>
<source>Protein Sci</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1002/pro.3909</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savastano</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.06.18.160648</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perdikari</surname>
<given-names>TM</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 nucleocapsid protein undergoes liquid-liquid phase separation stimulated by RNA and partitions into phases of human ribonucleoproteins</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.06.09.141101</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iserman</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Specific viral RNA drives the SARS CoV-2 nucleocapsid to phase separate</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.06.11.147199</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>IA</given-names>
</name>
<etal/>
</person-group>
<article-title>Partitioning of cancer therapeutics in nuclear condensates</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>1386</fpage>
<lpage>1392</lpage>
<pub-id pub-id-type="doi">10.1126/science.aaz4427</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agostini</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group>
<article-title>Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease</article-title>
<source>Mbio</source>
<year>2018</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.1128/mBio.00221-18</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>CJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency</article-title>
<source>J Biol Chem</source>
<year>2020</year>
<volume>295</volume>
<fpage>6785</fpage>
<lpage>6797</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.RA120.013679</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>1499</fpage>
<lpage>1504</lpage>
<pub-id pub-id-type="doi">10.1126/science.abc1560</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid review for the anti-coronavirus effect of remdesivir</article-title>
<source>Drug Discov Ther</source>
<year>2020</year>
<volume>14</volume>
<fpage>73</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.5582/ddt.2020.01015</pub-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKee</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stange</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Laufer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Naujokat</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Candidate drugs against SARS-CoV-2 and COVID-19</article-title>
<source>Pharmacol Res</source>
<year>2020</year>
<volume>157</volume>
<fpage>104859</fpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2020.104859</pub-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure of the RNA-dependent RNA polymerase from COVID-19 virus</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>779</fpage>
<lpage>782</lpage>
<pub-id pub-id-type="doi">10.1126/science.abb7498</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig.1</label>
<caption>
<title>SARS-CoV-2-N undergoes phase separation <italic>in vitro</italic> and <italic>in vivo</italic>.</title>
<p>
<bold>a</bold>, Bioinformatic analysis of the amino acid sequence of SARS-CoV-2-N. Schematic representation of the domain structure is shown on the top. IDR, intrinsically disorder region; NTD, N-terminal domain; CTD, C-terminal domain; IUPred, prediction of intrinsic disorder; PLD, prediction of prion-like region (PLAAC); FOLD, intrinsic disorder prediction by PLAAC (purple) and prion aggregation prediction by PAPA (black). Fold index is shown in gray. <bold>b</bold>, <italic>In vitro</italic> phase separation assays of 25 μM mEGFP tagged SARS-CoV-2-N protein (mEGFP-N). Scale bar, 20 μm. <bold>c</bold>, <italic>In vitro</italic> phase separation assays of 25 μM full-length SARS-CoV-2-N protein labeled with Alx546. Scale bar, 20 μm. <bold>d</bold>, Fusion of mEGFP-N (50 μM) condensates. Data are representative of three independent experiments. Scale bar, 2.5 μm <bold>e</bold>, <italic>In vitro</italic> FRAP analysis of the condensates (n=3) of mEGFP-N (3 μM). Top, representative snapshots of condensates before and after bleaching. Bottom, average fluorescence recovery traces of mEGFP-N condensates. Data are representative of three independent experiments and presented as mean ± SD. Scale bar, 1 μm. <bold>f</bold>, Fluorescence microscopy observations of mEGFP-N condensates <italic>in vitro</italic> depending on different sodium chloride concentrations and protein concentrations. Scale bar, 20 μm. <bold>g</bold>, <italic>In vivo</italic> FRAP analysis of the puncta of the expressed mCherry-N (SARS-CoV-2-N tagged with mCherry) in Vero-E6 cells. Insets, representative snapshots of puncta before and after bleaching. The bleached punctum is marked with an arrow. Scale bars, 10 μm (bottom), 2 μm (insets). <bold>h</bold>, The average fluorescence recovery traces of the puncta (n=3) of the expressed mCherry-N protein in Vero E6 cells presented in <bold>g</bold>. Data are representative of three independent experiments and presented as mean ± SD. <bold>i</bold>, Fluorescence time-lapse microscopy of Vero E6 cells expressing mCherry-N. In <bold>g</bold>, <bold>i</bold>, the “Red Fire” lookup table in the NIS-Elements Viewer was used to highlight the intensity difference. Two mCherry-N puncta are zoomed-in. Scale bars, 5 μm (bottom), 1 μm (insets).</p>
</caption>
<graphic xlink:href="EMS97919-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig.2</label>
<caption>
<title>Viral RNA facilitates phase condensation of SARS-CoV-2-N.</title>
<p>
<bold>a</bold>, Left, <italic>in vitro</italic> phase separation assays of mEGFP-tagged SARS-CoV-2-N (mEGFP-N) alone (375 nM) or Cy5-labeled 30-nt viral RNA alone (1.5 μM). Right, puncta formed by mEGFP-N (375 nM) mixed with 30-nt viral RNA (375 nM) <italic>in vitro</italic>. Scale bar, 5 μm. <bold>b</bold>, Fusion upon contact of the condensates of mEGFP-N (50 μM) with 30-nt viral RNA (25 μM). Scale bar, 2.5 μm. <bold>c</bold>, <italic>In vitro</italic> FRAP analysis of the condensates (n=3) of mEGFP-N (3 μM) with 30-nt viral RNA (1.5 μM). Top, representative snapshots of condensates before and after bleaching. Bottom, average fluorescence recovery traces of mEGFP-N with viral RNA in condensates. Data are representative of three independent experiments and presented as mean ± SD. Scale bar, 1 μm. <bold>d</bold>, <italic>In vitro</italic> phase separation assays of mEGFP-N with 30-nt viral RNA at different protein/RNA concentrations. Only the merged channel is shown here. Scale bar, 10 μm. <bold>e</bold>, Quantitative comparison of phase condensation of mEGFP-N with 30-nt viral RNA presented in <bold>d</bold>. <bold>f</bold>, <italic>In vitro</italic> phase separation assays of mEGFP-N with nucleic acids from distinct sources and at different concentrations. Only the merged channel is shown here. Scale bar, 20 μm. <bold>g</bold>, Quantitative comparison of phase condensation of mEGFP-N with nucleic acids presented in <bold>f</bold>. In <bold>e</bold> and <bold>g</bold>, %Area Occupied = [Sum of area occupied by N protein condensates]×100/[The whole area].</p>
</caption>
<graphic xlink:href="EMS97919-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig.3</label>
<caption>
<title>Excision of any domain and spontaneous missense mutations both compromise the LLPS of SARS-CoV-2-N-RNA complex.</title>
<p>
<bold>a</bold>, Diagram of the structural domains of SARS-CoV-2-N. Truncated proteins for functional analyses of different domains are shown underneath. <bold>b</bold>, <italic>In vitro</italic> phase separation assays of full-length (FL) mEGFP-N and truncations with 1.5 μM viral RNA at different concentrations of SARS-CoV-2-N (The numbers under the line represent the concentrations of the proteins). Scale bar, 20 μm. <bold>c</bold>, Quantitative comparison of the phase condensation of full-length and truncated mEGFP-N proteins presented in <bold>b</bold>. %Area Occupied = [Sum of area occupied by N protein condensates]×100/[The whole area]. <bold>d</bold>, Frequencies of spontaneous missense mutations in the N protein in 61,003 SARS-CoV-2 genome sequences from the China National Center for Bioinformation. Residue positions of the top 10 most frequent missense mutations are labeled. Bottom, arc diagram of double missense mutations. Only those double missense mutations with frequencies more than 0.0001 are shown. <bold>e</bold>, <italic>In vitro</italic> phase separation assays of the Alx546-labeled wild-type (WT) N protein and four mutants with mutations on the serine-arginine (SR) rich region with viral RNA of different concentrations. The ratio of N protein to viral RNA was 1:1. Scale bar, 20 μm.</p>
</caption>
<graphic xlink:href="EMS97919-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig.4</label>
<caption>
<title>CVL218 and PJ34 bind to SARS-CoV-2-N and increase the internal dynamics of its condensates.</title>
<p>
<bold>a</bold>, <bold>b</bold>, Surface plasmon resonance (SPR) assays of CVL218 (<bold>a</bold>) and PJ34 (<bold>b</bold>) to the immobilized full-length SARS-CoV-2-N. Top, the chemical structures of CVL218 and PJ34, respectively. Bottom, SPR binding curves of SARS-CoV-2-N to CVL218 and PJ34, respectively. <bold>c</bold>, <italic>In vitro</italic> phase separation assays of 3 μM mEGFP-N (SARS-CoV-2-N tagged with mEGFP) with viral RNA of different concentrations and in the presence of 20 μM DMSO, CVL218 and PJ34, respectively. Only the merged channel is shown here. Scale bar, 10 μm. <bold>d</bold>, <italic>In vitro</italic> FRAP analysis of droplets (n=3) formed by mEGFP-N protein with viral RNA (mEGFP-N, 3 μM; RNA, 3 μM) under the treatment of 20 μM DMSO, CVL218 and PJ34, respectively. Data are representative of three independent experiments and presented as mean ± SD. <bold>e</bold>, Representative snapshots of condensates before and after bleaching presented in <bold>d</bold>. Scale bar, 2 μm.</p>
</caption>
<graphic xlink:href="EMS97919-f004"/>
</fig>
<fig id="F5" position="float">
<label>Fig.5</label>
<caption>
<title>CVL218 and PJ34 influence the morphology and internal dynamics of the condensates of SARS-CoV-2-N-RNA-nsp12 complex.</title>
<p>
<bold>a</bold>, Schematic diagram of the structure of RNA-dependent RNA polymerase (RdRp) complex. Top, domain architectures of nsp12, nsp7 and nsp8, respectively. Bottom, a ribbon and surface view of the overall structure of RdRp complex (PDB code: 6yyt). <bold>b</bold>, <italic>In vitro</italic> phase separation assays for 3 μM Alex546 labeled nsp12 (purple) alone, with 3 μM mEGFP-N (SARS-CoV-2-N tagged with mEGFP, green) and with the complex of 3 μM mEGFP-N and 3 μM Cy5-labeled viral RNA (red), respectively. The molar ratio between mEGFP-N and RNA is 1:1. Scale bar, 2 μm. <bold>c-e</bold>, <italic>In vitro</italic> phase separation assays of 3 μM mEGFP-N protein with 3 μM viral RNA in the absence and presence of 3 μM nsp12 under the treatment of 20 μM DMSO (<bold>c</bold>), CVL218 (<bold>d</bold>) and PJ34 (<bold>e</bold>), respectively. Scale bar, 2 μm. <bold>f</bold>, Quantification of the effect of CVL218 or PJ34 treatment on the average diameters of the condensates presented in <bold>c-e</bold>. The diameters were measured from the fluorescence microscopy images and shown as mean±SD over three independent experiments. P values were determined by one-way analysis of variance (ANOVA) with Tukey's multiple comparison test, **: P &lt; 0.01, ***: P &lt; 0.001, ****: P &lt; 0.0001. <bold>g</bold>, <italic>In vitro</italic> FRAP analysis of the condensates (n=3) of SARS-CoV-2-N-RNA-nsp12 complex (mEGFP-N, 3 μM; RNA, 3 μM; nsp12, 3 μM) under the treatment of 20 μM DMSO, CVL218 and PJ34, respectively. Data are representative of three independent experiments and presented as mean ± SD. <bold>h</bold>, Representative snapshots of the condensates before and after bleaching presented in <bold>g</bold>. Scale bar, 2 μm. <bold>i</bold>, A model mechanism of the inhibition of viral replication and transcription of SARS-CoV-2 by small molecules in a phase separation dependent manner. Nsp12 alone cannot undergo phase separation <italic>in vitro</italic>, but it can be recruited into the droplets of SARS-CoV-2-N-RNA complex, despite the fact that nsp12 and viral RNA can form solid-state condensates (see <xref ref-type="fig" rid="F10">Extended Data Fig. 5</xref>). Comparing to those with DMSO treatment, the diameters and mobility of SARS-CoV-2-N-RNA-nsp12 droplets obviously increased after the treatment of CVL218/PJ34, which can attenuate the local density of the condensates and thus promote the entrance of other antiviral drugs (e.g., remdesivir) into their targets (e.g., nsp12/RdRp).</p>
</caption>
<graphic xlink:href="EMS97919-f005"/>
</fig>
</floats-group>
</article>
